MP-2026-ARL-G · Aurelin · Immunology / Atopic dermatitis
PRD planning workflow. The current state is highlighted.
Phase III readout expected Q2 2027. Establish scientific platform for oral JAK1/TYK2 selectivity and prepare dermatology KOL landscape.
Long-term safety versus existing JAK inhibitors
Adolescent data
No project yet
SO-ARL-01
Early scientific exchange builds understanding of the selectivity hypothesis.
Linked initiatives (1)
Planned versus delivered, and activity versus outcome for this product.
Initiatives completed
0 / 1
0 at risk or blocked
Milestones
0 / 2 done
0 on time · 0 late · 0 overdue · 2 upcoming
Budget consumed
46%
$880k of $1.9M · initiatives $0 of $120k
Activity → outcome
14 → 2 → 0
Engagements → insights → actions for this product
Activity counts (engagements) are not outcomes. Insights and actions are shown alongside so that activity is read against what it produced. Budget figures for the plan come from Finance; initiative spend is entered by initiative owners.
Newest first. Each version records who changed the plan and what changed.
08 Sept 2026 · v2
Revised after Clinical Development comments.
By Dr. Tomás Ferreira · current version
03 Jun 2026 · v1
Draft mid-year plan following Phase IIb data.
By Dr. Tomás Ferreira
| Initiative | Type | Objective | Owner | Priority | Status | Progress | End |
|---|---|---|---|---|---|---|---|
| Dermatology KOL landscape mapping | Medical strategy initiative | SO-ARL-01 | TFDr. Tomás Ferreira | Medium | Planned | 10% | 28 Feb 2027 |
| Timestamp | Action | User | Field | Change | Reason | Source |
|---|---|---|---|---|---|---|
| 08 Sept 2026, 15:30 UTC | Update | TFDr. Tomás Ferreira | version | 1 → 2 | Revised after Clinical Development comments | UI · AUD-001655 |